These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 25998972

  • 21. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [Abstract] [Full Text] [Related]

  • 22. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.
    Bryant RV, Winer S, Travis SP, Riddell RH.
    J Crohns Colitis; 2014 Dec; 8(12):1582-97. PubMed ID: 25267173
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
    Papi C, Fascì-Spurio F, Rogai F, Settesoldi A, Margagnoni G, Annese V.
    Dig Liver Dis; 2013 Dec; 45(12):978-85. PubMed ID: 24018244
    [Abstract] [Full Text] [Related]

  • 27. Immunomodulatory Effects of Flavonoids in the Prophylaxis and Treatment of Inflammatory Bowel Diseases: A Comprehensive Review.
    Ribeiro D, Proenca C, Rocha S, Lima JLFC, Carvalho F, Fernandes E, Freitas M.
    Curr Med Chem; 2018 Dec; 25(28):3374-3412. PubMed ID: 29446723
    [Abstract] [Full Text] [Related]

  • 28. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A.
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
    McRae BL, Levin AD, Wildenberg ME, Koelink PJ, Bousquet P, Mikaelian I, Sterman AS, Bryant S, D'Haens G, Kamath R, Salfeld J, van den Brink GR.
    J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
    [Abstract] [Full Text] [Related]

  • 31. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Rutgeerts P, Vermeire S, Van Assche G.
    Gut; 2007 Apr; 56(4):453-5. PubMed ID: 17369375
    [Abstract] [Full Text] [Related]

  • 32. Clinical pharmacology of inflammatory bowel disease therapies.
    Sandborn WJ, Faubion WA.
    Curr Gastroenterol Rep; 2000 Dec; 2(6):440-5. PubMed ID: 11079044
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mucosal healing with anti-TNF antibodies.
    Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L.
    Digestion; 2012 Dec; 86 Suppl 1():16-22. PubMed ID: 23051722
    [Abstract] [Full Text] [Related]

  • 35. [Evolving therapeutic targets in inflammatory Bowel Disease: mucosal healing as an emerging end point].
    Condino G, Margagnoni G, Aratari A, Luchetti R, Papi C.
    Recenti Prog Med; 2015 Nov; 106(11):564-9. PubMed ID: 26668042
    [Abstract] [Full Text] [Related]

  • 36. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
    Stadnicki A, Mazurek U, Plewka D, Wilczok T.
    Int Immunopharmacol; 2003 Jul; 3(7):939-44. PubMed ID: 12810351
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
    Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, Hébuterne X, Piche T.
    Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.